Health and Healthcare
Analysts Adjust Predictions on Medivation Buyout Price
Published:
Last Updated:
One time when missing earnings estimates doesn’t matter much is when there is bidding war for the company. That’s the position that Medivation Inc. (NASDAQ: MDVN) found itself in after reported a substantial earnings miss after markets closed last Thursday.
The company reported adjusted earnings per share of $0.11, less than half the consensus estimate of $0.23. Shares rose anyway, up 1.3% by Friday’s close at $60.
Medivation has rejected as “opportunistic” a buyout offer valued at around $9.3 billion from Sanofi (NYSE: SNY). That was $52.50 per share, but that almost certainly won’t be enough. Big pharma guns including Pfizer Inc. (NYSE: PFE) and Amgen Inc. (NASDAQ: AMGN) have also been mentioned as possible bidders. and Medivation may be worth as much as $70 a share to some of Sanofi’s potential challengers.
Medivation stock closed at $60.00 on Friday, up 1.3% for the day, in a 52-week range of $26.41 to $66.40. The consensus price target is $60.17, although many of these changes may not be included yet. The high target is $76 and the low target is $39.
Let’s face it: If your money is just sitting in a checking account, you’re losing value every single day. With most checking accounts offering little to no interest, the cash you worked so hard to save is gradually being eroded by inflation.
However, by moving that money into a high-yield savings account, you can put your cash to work, growing steadily with little to no effort on your part. In just a few clicks, you can set up a high-yield savings account and start earning interest immediately.
There are plenty of reputable banks and online platforms that offer competitive rates, and many of them come with zero fees and no minimum balance requirements. Click here to see if you’re earning the best possible rate on your money!
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.